A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin

• Main Authors: Peter Couroux (Author), Alexandre Brkovic (Author), Jason L. Vittitow (Author), Robert J. Israel (Author), Chinna Pamidi (Author), Jignesh Patel (Author), Maxime Barakat (Author)
• Format: Book
• Published: Wiley, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12-18 h per day, 3-7 days), limiting clinical utility. A reduction in tre...